Latest News
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
The anti-amyloid therapy will go off the market later this year.
In this Issue
- President’s Corner
- New Blood Test Detects Unique Biomarker for Alzheimer’s
- Researcher Spotlight: Kevin Beier, PhD
- Medications That Can Mimic Dementia
- Help Fight Alzheimer’s Through a Donor Advised Fund
In a new BrightFocus-funded study, researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults.
BrightFocus Foundation’s Alzheimer’s Fast Track, an immersive workshop for early-career scientists, was held Nov. 8-10 in Washington, D.C. and convened 80 talented Alzheimer’s researchers from 19 U.S. states and six countries, including Japan, Spain, and Sweden.
To achieve true health equity, we must ensure that all populations have equitable access to clinical trials and the benefits of medical research. With the right mix of resources, dedication, compassion, patience, and time, we can positively impact communities nationwide, write BrightFocus President and CEO Stacy Pagos Haller and board member Tonya M. Matthews, PhD, in a new op-ed.
